Nuveen
CLVS

Nuveen’s Clovis Oncology, Inc. CLVS Stock Holding History

Nuveen’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-549,293
Closed -$32.4M – 3593
2022
Q1 		$32.4M Buy
549,293
+188,405
+52% +$370K 0.01% 877
2021
Q4 		$21.3M Buy
360,888
+51,495
+17% +$190K 0.01% 1196
2021
Q3 		$18.3M Buy
309,393
+3,523
+1% +$17K 0.01% 1328
2021
Q2 		$18M Sell
305,870
-103,735
-25% -$608K 0.01% 1449
2021
Q1 		$24.2M Buy
409,605
+11,323
+3% +$75.9K 0.01% 1181
2020
Q4 		$23.5M Buy
398,282
+4,425
+1% +$22.4K 0.01% 1146
2020
Q3 		$23.2M Buy
393,857
+41,125
+12% +$246K 0.01% 969
2020
Q2 		$20.8M Buy
352,732
+4,824
+1% +$36.5K 0.01% 1021
2020
Q1 		$2.21M Buy
347,908
+8,459
+2% +$67.9K ﹤0.01% 2138
2019
Q4 		$3.54M Sell
339,449
-75,298
-18% -$548K ﹤0.01% 2165
2019
Q3 		$1.63M Buy
414,747
+44,037
+12% +$356K ﹤0.01% 2493
2019
Q2 		$5.51M Buy
+370,710
New +$6.7M ﹤0.01% 1932
2018
Q1 		– Sell
-12,265
Closed -$834K – 1156
2017
Q4 		$834K Sell
12,265
-65
-0.5% -$4.54K 0.01% 795
2017
Q3 		$1.02M Buy
12,330
+5,130
+71% +$407K 0.01% 762
2017
Q2 		$674K Buy
+7,200
New +$441K ﹤0.01% 853
2015
Q3 		– Sell
-18,314
Closed -$1.61M – 1630
2015
Q2 		$1.61M Buy
18,314
+1,354
+8% +$116K 0.01% 935
2015
Q1 		$1.26M Buy
16,960
+4,891
+41% +$345K 0.01% 1070
2014
Q4 		$676K Buy
+12,069
New +$634K ﹤0.01% 1303

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Nuveen's CLVS Position: Q2 2022 in Review

Nuveen sold out of Clovis Oncology, Inc. (CLVS) in Q2 2022, closing a stake of 549,293 shares — an estimated $32.4M sold.

Nuveen first reported a position in CLVS in Q4 2014 and held it in 18 quarters. The position peaked at $32.4M in Q1 2022. 115 funds tracked by Wall St. Rank hold CLVS as of Q2 2022.

  • Nuveen reported no remaining Clovis Oncology, Inc. position as of Q2 2022 after selling out during the quarter.
  • Nuveen sold 549,293 Clovis Oncology, Inc. shares in Q2 2022, an estimated $32.4M.
  • Nuveen first reported a position in Clovis Oncology, Inc. in Q4 2014 and held it in 18 quarters.
  • Nuveen's Clovis Oncology, Inc. position peaked at $32.4M in Q1 2022.
  • 115 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.